Zetia

Type: Product
Name: Zetia
First reported 22 hours ago - Updated 22 hours ago - 1 reports

Studies find new drugs greatly lower cholesterol

A new class of experimental medicines can dramatically lower cholesterol, raising hopes of a fresh option for people who can't tolerate or don't get enough help from Lipitor and other statin drugs that have been used for this for decades.The first large ... [Published Malta Independent Daily - 22 hours ago]
First reported Apr 13 2014 - Updated Apr 14 2014 - 1 reports

The Cost to Treat Cholesterol Plummets, But Will It Last?

Every year, Express Scripts crunches the previous year's data to uncover payer spending trends. One of the most encouraging of those trends is the steep drop-off in spending on cholesterol-lowering drugs.Last year, health care payers forked over 14% less ... [Published Motley Fool - Apr 13 2014]
First reported Apr 08 2014 - Updated Apr 08 2014 - 1 reports

The Biggest Biotech Clinical Wins of the Week

Last week was another great one for clinical trial results, although you wouldn't know it looking at biotech and pharmaceutical stock prices. Amgen (NASDAQ: AMGNLook out ZetiaAmgen continued marching ahead in the race to develop next-generation cholesterol-lowering ... [Published Motley Fool - Apr 08 2014]
First reported Apr 05 2014 - Updated Apr 05 2014 - 1 reports

Studies Find New Drugs Greatly Lower Cholesterol

WASHINGTON - A new class of experimental medicines can dramatically lower cholesterol, raising hopes of a fresh option for people who can't tolerate or don't get enough help from Lipitor and other statin drugs that have been used for this for decades ... [Published Sudan Vision Daily - Apr 05 2014]
First reported Apr 03 2014 - Updated Apr 03 2014 - 1 reports

Does Amgen Have the Next Lipitor on Its Hands?

Amgen, Inc ( NASDAQ: AMGN     ) was a big winner coming out of the American College of Cardiology Conference, where it presented five new phase 3 studies on evolocumab, part of the likely next generation of cholesterol drugs.Most cholesterol medications ... [Published Motley Fool Discussion Boards - Apr 03 2014]
First reported Apr 01 2014 - Updated Apr 01 2014 - 1 reports

Trials confirm potent efficacy of PCSK9s

Analyst gives PCSK9 previewPCSK9 inhibitors are vying to be the next go-to class of cholesterol-lowering treatments, and data presented at the 2014 American Cardiology Conference (ACC) this past weekend show why.Amgen's evolocumab, also known as AMG-145 ... [Published Medical Marketing And Media - Apr 01 2014]
First reported Mar 30 2014 - Updated Mar 31 2014 - 4 reports

New type of anti-cholesterol treatment shows hope in trials

A new class of experimental medicines can dramatically lower cholesterol, raising hopes of a fresh option for people who cannot tolerate or do not get enough help from statins.The first large studies of the drugs were presented over the weekend at an ... [Published Nursing Times - Mar 31 2014]
First reported Mar 29 2014 - Updated Mar 30 2014 - 6 reports

New drug greatly lowers cholesterol, study finds

WASHINGTON — A new class of experimental medicines can dramatically lower cholesterol, raising hopes of a fresh option for people who can’t tolerate or don’t get enough help from Lipitor and other statin drugs that have been used for this for decades ... [Published Providence Journal - Mar 30 2014]
First reported Mar 27 2014 - Updated Mar 28 2014 - 1 reports

Amgen - On Course To Change The Future

SummaryAmgen has 16 drugs in pipeline that are in the final testing phase with most of them expected to indicate pivotal findings in the present year. T-vec could be a breakthrough drug bringing robust growth in Amagn’s top line. Amgen is on course ... [Published Seeking Alpha - Mar 27 2014]
First reported Mar 24 2014 - Updated Mar 24 2014 - 1 reports

Ezetimibe In the Marketplace

Several years ago, the Schering-Plough cholesterol absorption inhibitor (Zetia, ezetimibe) and its combination pill with simvastatin (Vytorin) were the subject of a lot of puzzled controversy. A clinical trial (ENHANCE) looking at arterial wall thickness ... [Published In the Pipeline - Mar 24 2014]
First reported Mar 21 2014 - Updated Mar 21 2014 - 1 reports

Here's How Amgen May Help Merck

Advancing AMG-145 through regulators may not prove just a win for Amgen. It may also breathe much needed new life in Merck's (NYSE: MRK Developing new ways to lower cholesterolThe use of statins, like generic Lipitor and AstraZeneca's (NYSE: AZNThe impact ... [Published Motley Fool - Mar 21 2014]
First reported Mar 19 2014 - Updated Mar 19 2014 - 1 reports

Old guidelines boosted Zetia prescriptions

Despite new US cholesterol guidelines and a clinical trial that tamped down hopes that Merck's cholesterol drug Zetia could make a difference in the rare disease space, an analysis of prescription trends found that the drug continues to plug along, earning ... [Published Medical Marketing And Media - Mar 19 2014]

Quotes

"Although we cannot comment on the likelihood of approval based solely on specific indications or populations" two drugs recently were approved based on cholesterol-lowering for people with inherited conditions, she noted
...Analysts at IIFL expect 10-13 product launches in FY15 and business growth to pick up 12-14% conservatively. They add, "We expect Glenmark's US generics business to recover in FY15, from the lacklustre growth rate we saw in FY14. FY14 was the worst ever year with the business likely to end the year with just around 10% in constant currency growth."
...Kynamro comes with a boxed warning citing a risk of hepatic toxicity. There were "no elevations of liver enzymes greater than three times the upper limit of normal" among the 20 patients dosed with ISIS-APOCIII...
Evolocumab's LDL-lowering rates of roughly 50%-60% across multiple patient populations "support the safety and tolerability of the antibody,” wrote ISI Group analyst Mark Schoenebaum in an investor note this morning."

More Content

All (53) | News (48) | Reports (0) | Blogs (4) | Audio/Video (0) | Fact Sheets (1) | Press Releases (0)
sort by: Date | Relevance
Studies find new drugs greatly lower cholesterol [Published Malta Independent Daily - 22 hours ago]
The Cost to Treat Cholesterol Plummets, But Wil... [Published Motley Fool - Apr 13 2014]
US approvals key to Glenmark's prospects [Published Business Standard India - Apr 09 2014]
ODYSSEY MONO: Alirocumab monotherapy superior t... [Published Orthopedics Today - Apr 09 2014]
US approvals hold key to Glenmark's prospects [Published Business Standard India - Apr 09 2014]
The Biggest Biotech Clinical Wins of the Week [Published Motley Fool - Apr 08 2014]
Changing Guidelines for Hypertension and Hyperc... [Published Cenla Focus - Apr 07 2014]
Studies Find New Drugs Greatly Lower Cholesterol [Published Sudan Vision Daily - Apr 05 2014]
Does Amgen Have the Next Lipitor on Its Hands? [Published Motley Fool Discussion Boards - Apr 03 2014]
How Did A 30 Year Big Pharma Veteran Become An ... [Published Forbes.com - Apr 01 2014]
Trials confirm potent efficacy of PCSK9s [Published Medical Marketing And Media - Apr 01 2014]
Amgen Stock Gets Bump Up On Cholesterol Drug Data [Published Investor's Business Daily - Mar 31 2014]
Physician Views: Life Beyond Statins - What Opp... [Published PR inside - Mar 31 2014]
Today’s Top Biotech Stories: Curis, Amgen, and ... [Published Motley Fool Discussion Boards - Mar 31 2014]
Tomorrow's cardio blockbusters: Inside 'the nex... [Published FierceBiotech - Mar 31 2014]
New type of anti-cholesterol treatment shows ho... [Published Nursing Times - Mar 31 2014]
PCSK9 Inhibitors Showing Big Results in Early T... [Published American Journal of Public Health - Mar 30 2014]
New drugs greatly lower cholesterol, studies show [Published Lehigh Valley Live - Mar 30 2014]
Evolocumab Results Unveiled at Packed Session: ... [Published American Journal of Managed Care - Mar 30 2014]
Evolocumab shows promise in GAUSS-2, LAPLACE-2 ... [Published Orthopedics Today - Mar 30 2014]
Amgen presents additional positive Phase III re... [Published FirstWord Pharma - Mar 30 2014]
New Drug Lowers Cholesterol Beyond What Statins... [Published Health Finder - Mar 30 2014]
In brief | Nation & World, March 30, 2014 [Published West Hawaii Today - Mar 30 2014]
Amgen's PCSK9 drug slashes 'bad' cholesterol in... [Published FierceBiotech - Mar 30 2014]
New drug greatly lowers cholesterol, study finds [Published Providence Journal - Mar 30 2014]
New class of experimental medicines can dramati... [Published Washington Post - Mar 30 2014]
Drug firms develop options to statins to cut ch... [Published Pittsburgh Tribune Review - Mar 30 2014]
Studies find new drugs greatly lower cholesterol [Published Leaf Chronicle - Mar 30 2014]
Studies Find New Drugs Greatly Lower Cholesterol [Published TIME.com - Mar 29 2014]
Studies find new drugs greatly lower cholesterol [Published Contra Costa Times - Mar 29 2014]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Studies Find New Drugs Greatly Lower Cholesterol [Published TIME.com - Mar 29 2014]
(WASHINGTON) — A new class of experimental medicines can dramatically lower cholesterol, raising hopes of a fresh option for people who can’t tolerate or don’t get enough help from Lipitor and other statin drugs that have been used for this for decades. ...
Ezetimibe In the Marketplace [Published In the Pipeline - Mar 24 2014]
Several years ago, the Schering-Plough cholesterol absorption inhibitor (Zetia, ezetimibe) and its combination pill with simvastatin (Vytorin) were the subject of a lot of puzzled controversy. A clinical trial (ENHANCE) looking at arterial wall thickness ...
Drug Patent Expirations for March 21 2014 [Published Biotech Blog - Mar 22 2014]
Copyright © thinkBiotech If your reader cannot render the information below, go tohttp://www.DrugPatentWatch.com/innovation to see the latest expirationsbody { font-family:Calibri, tahoma, arial,sans-serif;}table { font-size:12px; font-family:Calibri, ...
Merck Recalls All Supply of Combo Cholesterol Drug [Published The Curious Capitalist - Jan 14 2014]
(TRENTON, N.J.) — Drugmaker Merck & Co. said Tuesday that it’s recalling a combination cholesterol drug, wiping out the entire U.S. stock, due to packaging defects that could reduce effectiveness. Merck said the recall covers all four dose strengths and ...
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.